HER2 is overexpressed and/or amplified in about 20% of breast cancers and signals aggressive tumor behavior. However, it also opens the door for targeted therapeutic options, and patients with advanced or metastatic disease are now seeing greatly improved prognoses with the emergence of new anti-HER2 therapies. But with more options comes more complexity.
In this interactive Digital Flashcards activity, you will work through 3 different patient cases of HER2-positive metastatic breast cancer. Can you choose the best treatment options? These patient scenarios will test your knowledge and experiences—are you up for the challenge?
Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about this data, please visit here.